Yi Shen Email & Phone Number

Princeton, Nj, Us

Durham, North Carolina, Us

Oncology | NDD | Infectious Diseases

Wesley Chapel, Florida, Us

Clinical-stage biotech company focused on advancing cell-based therapies for difficult-to-treat solid tumors and infectious diseases.

Princeton, New Jersey, Us

I was hired as a key member of the executive team to support the CEO in establishing Luzsana (NewCo) as the wholly owned US subsidiary of the largest pharma company in China, Jiangsu Hengrui Pharmaceuticals, as well as in executing Luzsana's capital market strategy. I was accountable for asset and enterprise valuation, strategic and operational planning, project and portfolio management, fundraising, and supporting Board of Directors meetings. I reported to the CEO.Notable Accomplishments: Directed internal and external teams in completing a complex asset assessment and prioritization, yielding a portfolio of 11 assets (mainly oncology, PD-1 inhibitor, ADCs, etc.) comprised of first-in-class and best-in-class potential drug candidates in the US, EU, and Japan. Pioneered and applied best-in-class frameworks to comprehensively qualify, quantify, and prioritize strategic value for 16 assets driven by commercial potential, clinical, regulatory, and operational feasibility, recommendations gaining board approval.

Dublin, Oh, Us

I was sought out by Chief Quality and Regulatory Affairs Officer of Cardinal Health to strategize, develop, and implement a multiyear plan that instituted needed people, process, and technology enhancements across the entire product lifecycle of the $500M EU portfolio. While here, I reported to the Chief Quality and Regulatory Affairs Officer.Notable Accomplishments: Led PMO in operationalizing Board of Directors-sponsored and Operating Committee-governed program with 160+ deliverables and $17M budget, earning the Board’s trust by delivering results that exceeded expectations. Built a two-year, enterprise-wide infrastructure from the ground up of people (~100-member cross-functional team and an 8-member project management team), process, and technology to identify, design, and implement must-have enhancements required by an additional 115 new pages of EU Medical Device Regulatory (MDR) requirements, ensuring sales of ~$500M in EU. Secured program funding by providing Marketing, R&D, Regulatory, Quality, Medical Affairs, IT, and Supply Chain with frameworks and templates on performing activity-based budget planning.

As the Associate Principal it was my job was to help major pharma clients to solve critical commercial strategy and operational problems. I led engagement teams in collaboration efforts with clients to develop solutions. Notable Accomplishments: Developed the client’s first-ever CEO approved agile launch strategy for a type-2 diabetes GLP-1 product, which achieved $5 Billion in global sales in 2022. Managed all aspects of global patient advocacy strategy engagement for a leading pharma’s rare disease franchise, providing frameworks and templates with step-by-step instructions focused on strategic and tactical planning for any disease area in any market.

Worldwide, Oo

During my time at Deloitte Consulting, I solved critical strategy and operational problems for major healthcare clients for the largest global management consultancy offering Strategy and Innovation, Technology, Digital, and Human Capital expertise. I led 20+ successful strategic and operational projects in biotech, pharma, and adjacent sectors with oversight of 20 direct reports over five years.Notable Accomplishments: Increased revenue by 150% by earning additional opportunities for 85% of completed projects.  Led the engagement and executive-level teams in the development of a five-year growth strategy by establishing vision, identifying and prioritizing 50+ opportunities to address affordability and improvement, and creating an execution roadmap, yielding up to $400M+ in annual incremental revenue and cost savings.  Drove multiple global drug launches by generating market and competitive insights, developing overall and various aspects of launch strategies (Orphan Drug Global Launch, Supply Chain Consignment Strategy, and Respiratory Drug US Launch), and supporting implementation.

Basel, Baselstadt, Ch

2-year Post-MBA Marketing Development Program ONCOLOGY sales (Zometa, Femara, and Afinitor): Delivered #1 Zometa volume growth in nation  Brand Management (Xolair); Market Research Supporting Novartis Respiratory Franchise (Xolair and TOBI)

Basel, Baselstadt, Ch

Rahway, New Jersey, Us

Us

Mba, Healthcare Management, Strategy, Marketing

Master Of Science (Ms), Separation Science / Analytical Chemistry